Back to Search Start Over

Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection

Authors :
Grebely, J
Petoumenos, K
Hellard, M
Matthews, G
Suppiah, V
Applegate, TL
Yeung, B
Marks, P
Rawlinson, WD
Lloyd, AROLA
Booth, D
Kaldor, JM
George, J
Dore, GJ
Grebely, J
Petoumenos, K
Hellard, M
Matthews, G
Suppiah, V
Applegate, TL
Yeung, B
Marks, P
Rawlinson, WD
Lloyd, AROLA
Booth, D
Kaldor, JM
George, J
Dore, GJ
Publication Year :
2010

Abstract

Polymorphisms in the IL28B (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of IL28B in spontaneous and treatment-induced clearance following recent HCV infection. The Australian Trial in Acute Hepatitis C (ATAHC) was a study of the natural history and treatment of recent HCV, as defined by positive anti-HCV antibody, preceded by either acute clinical HCV infection within the prior 12 months or seroconversion within the prior 24 months. Factors associated with spontaneous and treatment-induced HCV clearance, includingvariations in IL28B, were assessed. Among 163 participants, 132 were untreated (n 5 52) or had persistent infection (infection duration 26 weeks) at treatment initiation (n 5 80). Spontaneous clearance was observed in 23% (30 of 132 participants). In Cox proportional hazards analysis (without IL28B), HCV seroconversion illness with jaundice was the only factor predicting spontaneous clearance (adjusted hazards ratio 5 2.86; 95% confidence interval 5 1.24, 6.59; P 5 0.014). Among participants with IL28B genotyping (n 5 102 of 163 overall and 79 of 132 for the spontaneous clearance population), rs8099917 TT homozygosity (versus GT/GG) was the only factor independently predicting time to spontaneous clearance (adjusted hazard ratio 5 3.78; 95% confidence interval 5 1.04, 13.76; P 5 0.044).Participants with seroconversion illness with jaundice were more frequently 099917 TT homozygotes than other (GG/GT) genotypes (32% versus 5%, P 5 0.047). Among participants adherent to treatment and who had IL28B genotyping (n 5 54), sustained virologic response was similar among TT homozygotes (18 of 29 participants, 62%) and those with GG/GT genotype (16 of 25, 64%, P 5 0.884). Conclusion: During recent HCV infection, genetic variations in IL28B region were associated with spontaneous but not treatmentinduced clearance. Early therapeutic intervention could be recomme

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1031075324
Document Type :
Electronic Resource